Pacira BioSciences (NASDAQ:PCRX) Earns “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Pacira BioSciences (NASDAQ:PCRX – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $57.00 price target on the stock. HC Wainwright also issued estimates for Pacira BioSciences’ Q1 2024 earnings at $0.38 EPS, Q2 2024 earnings at $0.51 […]
More Stories
Analyzing InterRent Real Estate Investment Trust (OTCMKTS:IIPZF) and Dynex Capital (NYSE:DX)
InterRent Real Estate Investment Trust (OTCMKTS:IIPZF – Get Free Report) and Dynex Capital (NYSE:DX – Get Free Report) are both...
Profire Energy (NASDAQ:PFIE) & Innovex International (NYSE:INVX) Head to Head Survey
Innovex International (NYSE:INVX – Get Free Report) and Profire Energy (NASDAQ:PFIE – Get Free Report) are both small-cap oils/energy companies,...
Vornado Realty Trust (NYSE:VNO) Rating Increased to Outperform at Mizuho
Mizuho upgraded shares of Vornado Realty Trust (NYSE:VNO – Free Report) from a neutral rating to an outperform rating in...
Toyota Motor (NYSE:TM) Upgraded to “Hold” at StockNews.com
StockNews.com upgraded shares of Toyota Motor (NYSE:TM – Free Report) from a sell rating to a hold rating in a...
Janone (NASDAQ:ALTS) and Connect Biopharma (NASDAQ:CNTB) Head-To-Head Review
Janone (NASDAQ:ALTS – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap finance companies, but...
Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com
StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research note published on Tuesday. The firm...